Nasus Pharma CEO Dan Teleman exits leadership roles

Nasus Pharma Ltd disclosed that Dan Benjamin Teleman has ceased to serve as Chief Executive Officer and resigned as a director on the Board of Directors, effective July 22, 2026.

Accepted by SEC EDGAR 07/29/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Nasus Pharma Ltd disclosed that Dan Benjamin Teleman has ceased to serve as Chief Executive Officer and resigned as a director on the Board of Directors, effective July 22, 2026. As a result, he is no longer subject to Section 16 reporting obligations regarding Nasus Pharma securities.

Key Figures

Reported equity transactions: 0 shares Effective date of role cessation: July 22, 2026 Net buy/sell direction: 0 shares

3 metrics

Reported equity transactions 0 shares No buy, sell, or derivative trades are listed in this Form 4 exit report

Effective date of role cessation July 22, 2026 Date Dan Benjamin Teleman ceased serving as CEO and resigned as director

Net buy/sell direction 0 shares NetBuySellShares is zero, reflecting no reported acquisitions or dispositions

Key Terms

Exit Form 4, Section 16, reporting obligations

3 terms

Exit Form 4 regulatory

"This Exit Form 4 has been filed solely to report that Reporting Person ceased"

Section 16 regulatory

"no longer subject to the reporting obligations under Section 16 of the Securities"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

reporting obligations regulatory

"and is no longer subject to the reporting obligations under Section 16"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the NSRX Form 4 exit report disclose?

It confirms that Dan Benjamin Teleman has stopped serving as Chief Executive Officer and resigned as a director of Nasus Pharma. The disclosure notes this leadership change and explains that he is no longer subject to Section 16 reporting obligations for the company.

When did Dan Benjamin Teleman leave his roles at Nasus Pharma (NSRX)?

His departure as Chief Executive Officer and as a director on the Board became effective on July 22, 2026. From that date, he is treated as no longer holding those positions for Section 16 insider reporting purposes at Nasus Pharma.

Does this NSRX Form 4 report any stock trades by Dan Benjamin Teleman?

No equity transactions are reported; the Form 4 serves solely to record Teleman’s change in status at Nasus Pharma. It indicates that he has ceased serving as CEO and director, without listing any share purchases, sales, or option exercises.

What is the significance of Section 16 for Nasus Pharma (NSRX) insiders?

Section 16 imposes reporting obligations on certain insiders for trades in company securities. The disclosure states that, after leaving his CEO and director roles, Dan Benjamin Teleman is no longer subject to these Section 16 reporting requirements for Nasus Pharma.

Is Dan Benjamin Teleman still considered an insider of Nasus Pharma (NSRX)?

Based on this disclosure, he is no longer subject to Section 16 insider reporting for Nasus Pharma. That change follows his effective July 22, 2026 departure as Chief Executive Officer and resignation from the company’s Board of Directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teleman Dan Benjamin

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Exit Form 4 has been filed solely to report that Reporting Person ceased to serve as the Chief Executive Officer of Nasus Pharma Ltd (the "Issuer") and resigned as Director from the Board of Directors, effective as of July 22, 2026, and is no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to the Issuer.

	/s/ Dan Benjamin Teleman	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)